Clay Siegall, Morphimmune CEO (Photo by Dimitrios Kambouris/Getty Images for Gabrielle's Angel Foundation)

May 18, 2023 10:28 AM EDTUpdated 11:18 AM

Shortly after Clay Siegall’s arrival, Philip Low’s Morphimmune nabs funds for twist on cancer therapies

Kyle LaHucik

Senior Reporter

Two months after announcing Clay Siegall’s arrival in the C-suite, Morphimmune has nabbed more funds to take its targeted cancer therapy bet toward the clinic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shortly after Clay Siegall’s arrival, Philip Low’s Morphimmune nabs funds for twist on cancer therapies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Shortly after Clay Siegall’s arrival, Philip Low’s Morphimmune nabs funds for twist on cancer therapies